Pancreatic cancer: Ukrainian and world tendencies

Authors

  • V.M. Kopchak State Institution “O.O. Shalimov National Institute of Surgery and Transplantology” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine,
  • I.I. Zaivelieva State Institution “O.O. Shalimov National Institute of Surgery and Transplantology” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine,

DOI:

https://doi.org/10.22141/2663-3272.3.1.2020.209824

Keywords:

pancreatic cancer, chemotherapy, gemcitabine, FOLFIRINOX, nab-paclitaxel, abraxane, review

Abstract

Pancreatic cancer is a malignant tumor that has a high metastasis potential and restrained sensitivity to chemotherapeutic treatment, characterized by a relatively poor prognosis for patients to recover, especially with diffused and unresectable forms. This article provides an overview of relevant clinical trials on the effectiveness of various chemotherapy programs, data of scientific search for the molecular typing of pancreatic cancer. We analyzed the studies on the chemotherapy in locally advanced and metastatic pancreatic cancer, compared the effectiveness of various schemes. Materials and interpretations of clinical trials ACCORD 11 MPACT; data from PubMed, NCCN, ESMO, ASCO, FDA data. Chemotherapy with a combination of gemcitabine and nab-paclitaxel shows better efficacy and prognostic prospects in the treatment of unresectable forms of pancreatic cancer, compared to all other programs. Adverse events related to treatment, including grades 3–4, are less commonly reported with gemcitabine + nab-paclitaxel rather than with polychemotherapy treatment by other schemes. Due to the lack of registration of nab-paclitaxel (abraxane) in Ukraine, the FOLFIRINOX is the program of choice for patients with a favorable comorbidity profile, but it is associated with frequent toxic effects in patients with pancreatic cancer.

References

http://www.ncru.inf.ua/ National Cancer Registry of Ukraine.

https://gco.iarc.fr/ Global Cancer Observatory.

Burris 3rd A.H., Moore M.J., Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997. Vol. 15. Р. 2403-13.

Cunningham D., Chau I., Stocken D.D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009. Vol. 27. Р. 5513-8.

Moore M.J., Goldstein D., Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007. Vol. 25. Р. 1960-6.

Conroy T., Paillot B., Franзois E. et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer — a Groupe Tumeurs Digestives of the Fйdйration Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. 2005. Vol. 23. Р. 1228-36.

Conroy T., Gavoille C., Samalin E., Ychou M., Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr. Oncol. Rep. Published online 23 January 2013.

Von Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013 Oct 31. Vol. 369(18). Р. 1691-703.

Muranaka T., Kuwatani M., Komatsu Y. et al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J. Gastrointest. Oncol. 2017 Jun. Vol. 8(3). Р. 566-571.

Gui-Feng Liu, Gui-Jie Li et al. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis. J. Cell Biochem. 2018 Jan. Vol. 119(1). Р. 511-523.

Shu-Hua Zhang, Gui-Feng Liu et al. Efficacy of Different Chemotherapy Regimens in Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis. J Cell Physiol. 2018 Apr. Vol. 233(4). Р. 3352-3374.

Xiao-Fang Wang, Wen-Feng Huang et al. Toxicity of Chemotherapy Regimens in Advanced and Metastatic Pancreatic Cancer Therapy: A Network Meta-Analysis. J. Cell Biochem. 2018 Jul. Vol. 119(7). Р. 5082-5103.

Chiorean E.G., Cheung W.Y. et al. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther. Adv. Med. Oncol. 2019. Vol. 11.

Neha P., Adnan Z. et al. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel. Pancreas J. of neuroendocrine tumors and pancreatic diseases and sciences. 2019. Vol. 48. Issue 7. Р. 920-926.

Desai N., Trieu V. et al. Improved Effectiveness of Nanoparticle Albumin-Bound (Nab) Paclitaxel Versus Polysorbate-Based Docetaxel in Multiple Xenografts as a Function of HER2 and SPARC Status. Anti-Cancer Drugs. October 2008. Vol. 19. Issue 9. Р. 899-909.

Fisher S., Fisher K. et al. Excision Repair Cross-Complementing gene-1, Ribonucleotide Reductase Subunit M1, Ribonucleotide Reductase Subunit M2, and Human Equilibrative Nucleoside transporter-1 Expression and Prognostic Value in Biliary Tract Malignancy. ACS Journals. Cancer, 2013 Jan 15. Vol. 119(2).

Р. 454-62.

Published

2020-02-01

Issue

Section

Review